Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Uric acid, the end product of purine metabolism in humans, is crucial because of its anti-oxidant activity and a causal relationship with hyperuricemia and gout. Several physiologically important urate transporters regulate this water-soluble metabolite in the human body; however, the existence of latent transporters has been suggested in the literature. We focused on the Escherichia coli urate transporter YgfU, a nucleobase-ascorbate transporter (NAT) family member, to address this issue. Only SLC23A proteins are members of the NAT family in humans. Based on the amino acid sequence similarity to YgfU, we hypothesized that SLC23A1, also known as sodium-dependent vitamin C transporter 1 (SVCT1), might be a urate transporter. First, we identified human SVCT1 and mouse Svct1 as sodium-dependent low-affinity/high-capacity urate transporters using mammalian cell-based transport assays. Next, using the CRISPR-Cas9 system followed by the crossing of mice, we generated Svct1 knockout mice lacking both urate transporter 1 and uricase. In the hyperuricemic mice model, serum urate levels were lower than controls, suggesting that Svct1 disruption could reduce serum urate. Given that Svct1 physiologically functions as a renal vitamin C re-absorber, it could also be involved in urate re-uptake from urine, though additional studies are required to obtain deeper insights into the underlying mechanisms. Our findings regarding the dual-substrate specificity of SVCT1 expand the understanding of urate handling systems and functional evolutionary changes in NAT family proteins.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011331PMC
http://dx.doi.org/10.1007/s00424-023-02792-1DOI Listing

Publication Analysis

Top Keywords

urate transporter
12
nat family
12
urate
10
vitamin transporter
8
svct1
8
transporter svct1
8
urate transporters
8
serum urate
8
transporter
5
svct1 serves
4

Similar Publications

Comprehensive management of tophaceous wounds.

Zhejiang Da Xue Xue Bao Yi Xue Ban

September 2025

Wound Healing Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.

Tophaceous wounds represent a severe complication of end-stage gout, characterized by the deposition of monosodium urate (MSU) crystals leading to localized tissue ischemia, chronic inflammation, and non-healing ulcers. The pathological mechanism involves the formation of MSU crystals under persistent hyperuricemia, inflammatory encapsulation, and mechanical compression of the vascular system due to tophus enlarge-ment, ultimately resulting in chronic non-healing ulcers. This article consolidates current evidence to outline an integrated management strategy for such wounds, combining systemic metabolic control with localized interventions.

View Article and Find Full Text PDF

The global increase in hyperuricemia, a pathological condition characterized by elevated serum urate concentrations, emphasizes the importance of appropriate management of uric acid homeostasis in the body. Enhancing renal urate excretion is clinically relevant to achieve serum urate-lowering, and the functional inhibition of urate transporter 1 (URAT1), a renal urate transporter involved in the reabsorption of urate, has been recognized as a promising strategy. In this context, natural substances, including food ingredients with URAT1-inhibitory activity, have garnered significant interest.

View Article and Find Full Text PDF

Dietary 1,3-diacylglycerol ameliorates hyperuricemia dual modulation of urate transporters and inflammasomes in mice.

Food Funct

August 2025

Department of Endocrinology, Affiliated Children's Hospital of Jiangnan University, Wuxi Children's Hospital, Wuxi, Jiangsu, China.

Hyperuricemia is a metabolic disorder associated with substantial health risks, whereas current clinical treatments frequently entail considerable adverse effects. This study demonstrates that dietary diacylglycerol (DAG) significantly ameliorates hyperuricemia by specifically modulating the renal urate transporter network and exerting anti-inflammatory effects. 1,3-Diacylglycerol (1,3-DAG) is metabolized into 1-monoacylglycerol in the body, which inhibits the synthesis of triglycerides.

View Article and Find Full Text PDF

Background: Albuminuria is an important indicator of kidney damage. It increases the risk of adverse outcomes such as end-stage renal failure and cardiovascular events. Dotinurad, a drug newly developed in Japan, selectively inhibits renal urate transporter 1.

View Article and Find Full Text PDF

Gout, caused by hyperuricemia, has a detrimental impact on patients'quality of life. The urate transporter 1 (URAT1) stands out as a key therapeutic target. However, its clinical development remains uncertain.

View Article and Find Full Text PDF